BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15226187)

  • 1. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences.
    Liu H; Wang J; Epner EM
    Blood; 2004 Oct; 104(8):2505-13. PubMed ID: 15226187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation.
    Krieger S; Grunau C; Sabbah M; Sola B
    Exp Hematol; 2005 Jun; 33(6):652-9. PubMed ID: 15911089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flipping the cyclin D1 switch in mantle cell lymphoma.
    Hasanali Z; Sharma K; Epner E
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):143-52. PubMed ID: 22687450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.
    Liu H; Huang J; Wang J; Jiang S; Bailey AS; Goldman DC; Welcker M; Bedell V; Slovak ML; Clurman B; Thayer M; Fleming WH; Epner E
    J Exp Med; 2008 Aug; 205(8):1843-58. PubMed ID: 18625744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
    Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
    Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
    Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
    J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
    Duan H; Heckman CA; Boxer LM
    Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
    Gabrea A; Bergsagel PL; Chesi M; Shou Y; Kuehl WM
    Mol Cell; 1999 Jan; 3(1):119-23. PubMed ID: 10024885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas.
    Aguilera NS; Bijwaard KE; Duncan B; Krafft AE; Chu WS; Abbondanzo SL; Lichy JH; Taubenberger JK
    Am J Pathol; 1998 Dec; 153(6):1969-76. PubMed ID: 9846986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
    Magdinier F; Wolffe AP
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
    Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
    J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
    Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A
    Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).
    Janssen JW; Vaandrager JW; Heuser T; Jauch A; Kluin PM; Geelen E; Bergsagel PL; Kuehl WM; Drexler HG; Otsuki T; Bartram CR; Schuuring E
    Blood; 2000 Apr; 95(8):2691-8. PubMed ID: 10753852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
    Markozashvili D; Pichugin A; Barat A; Camara-Clayette V; Vasilyeva NV; Lelièvre H; Kraus-Berthier L; Depil S; Ribrag V; Vassetzky Y
    Gene; 2016 Apr; 580(2):134-143. PubMed ID: 26774800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9.
    Shirato H; Ogawa S; Nakajima K; Inagawa M; Kojima M; Tachibana M; Shinkai Y; Takeuchi T
    J Biol Chem; 2009 Jan; 284(2):733-9. PubMed ID: 19010785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation by a DNA-associated form of cyclin D1.
    Bienvenu F; Barré B; Giraud S; Avril S; Coqueret O
    Mol Biol Cell; 2005 Apr; 16(4):1850-8. PubMed ID: 15659654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
    Vaandrager JW; Kluin P; Schuuring E
    Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex.
    Rampalli S; Pavithra L; Bhatt A; Kundu TK; Chattopadhyay S
    Mol Cell Biol; 2005 Oct; 25(19):8415-29. PubMed ID: 16166625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation.
    Schübeler D; Lorincz MC; Cimbora DM; Telling A; Feng YQ; Bouhassira EE; Groudine M
    Mol Cell Biol; 2000 Dec; 20(24):9103-12. PubMed ID: 11094062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
    Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
    Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.